Pharmacokinetics of Liposomal Amphotericin B (Ambisome) in Critically Ill Patients.

Antimicrobial Agents and Chemotherapy- United States

doi 10.1128/aac.41.6.1275

Full Text

Abstract

Available in

Date

Authors

Publisher

American Society for Microbiology

Related search

Biliary Amphotericin B Pharmacokinetics and Pharmacodynamics in Critically Ill Liver Transplant Recipients Receiving Treatment With Amphotericin B Lipid Formulations

International Journal of Antimicrobial Agents
MedicineInfectious DiseasesMicrobiologyPharmacology
2015English

Liposomal Amphotericin B (AmBisome) in the Treatment of Complicated Kala-Azar Under Field Conditions

Clinical Infectious Diseases
Infectious DiseasesMicrobiology
1995English

Pharmacokinetics of Micafungin in Critically Ill Patients

Scientific Reports
Multidisciplinary
2019English

Liposomal Amphotericin B

Medical mycology journal
Infectious DiseasesMicrobiology
2005English

Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Critically Ill and Non-Critically Ill AIDS Patients

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1995English

Population Pharmacokinetics of Anidulafungin in Critically Ill Patients

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
2019English

Population Pharmacokinetics of Dexmedetomidine in Critically Ill Patients

Clinical Drug Investigation
MedicinePharmacology
2013English

Altered Pharmacokinetics of Ceftazidime in Critically Ill Patients

Antimicrobial Agents and Chemotherapy
Infectious DiseasesPharmacology
1999English

Risk Factors for Visceral Leishmaniasis Relapse in Immunocompetent Patients Following Treatment With 20 Mg/Kg Liposomal Amphotericin B (Ambisome) in Bihar, India

PLoS Neglected Tropical Diseases
PharmacologyPublic HealthEnvironmentalToxicologyInfectious DiseasesPharmaceuticsOccupational Health
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy